HOw Patients view Extended half-life products: Impressions from real-world experience (The HOPE study).
extended half-life factors
haemophilia
patient expectation
patient experience
qualitative research
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
04
11
2018
revised:
27
01
2019
accepted:
20
05
2019
pubmed:
1
8
2019
medline:
8
2
2020
entrez:
1
8
2019
Statut:
ppublish
Résumé
Extended half-life (EHL) clotting factors have been shown to offer people with haemophilia (PwH) protection from bleeding with fewer infusions, which might reduce treatment burden. The HOw Patients view Extended half-life products (HOPE) study aimed to explore, understand and describe patient expectations around the prophylactic use of EHL products and to establish whether these expectations were met through individual follow-up analysis. The HOPE study was a prospective, qualitative cohort study conducted among PwH who had switched to Fc fusion protein EHL products in routine clinical care and who had not been recruited to clinical trials of these products. Semi-structured audio-recorded interviews were undertaken over two time points; transcripts were analysed to systematically generate theory from data that contains both inductive and deductive thinking. Forty-three interviews were conducted with 25 participants. Most participants were positive about EHL treatment and intended to continue using them. Reduced frequency of infusions meant lives were less disrupted or dominated by haemophilia, and there was less perceived stress on overused veins. For those PwH who did not reduce infusion frequency, there were other perceived benefits from EHLs with respect to greater protection with higher trough levels and fewer bleeds. Patients switching to EHL treatments believe these products will result in fewer infusions and less disruption of everyday life, leaving them feeling more protected with fewer bleeds and increased activity levels, as well as enhanced well-being and mental health. Understanding patient expectation and experience around using products adds real-world data to clinical trial experience.
Substances chimiques
Blood Coagulation Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
814-820Subventions
Organisme : Sobi
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126:1078-1085.
Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22:487-498.
Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119:3031-3037.
Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317-325.
Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313-2323.
Santagostino E, Martinowitz U, Lissitchkov T, et al. Long acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127(14):1761-1769.
Kings Fund. The Kings Fund Experience Based Co-Design Toolkit. https://www.kingsfund.org.uk/projects/ebcd. Accessed October 20, 2018.
Charmaz K. Constructing Grounded Theory, 2nd edn. Thousand Oaks, CA: Sage; 2014.
Ward K, Gott M, Hoare K. Participants views of telephone interviews within a grounded theory study. J Adv Nurs. 2015;71(12):2775-2785.
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77-101.
Jenkinson C, Coulter A, Bruster S. The Picker Patient Experience questionnaire: development and validation using data from in-patient surveys in five countries. Int J Qual Health Care. 2002;14(5):353-358.
von Mackensen S, Kalnins W, Krucker J, et al. Haemophilia patients’ unmet needs and their expectations of the new extended half-life factor concentrates. Haemophilia. 2017;4:566-574.
Chaugule SS, Hay JW, Young G. Understanding patient preferences and willingness to pay for hemophilia therapies. Patient Prefer Adherence. 2015;9:1623-1630.
Schwartz C, Powell VE, Su J, Zhang J, Eldar-Lissai A. The impact of extended half-life versus conventional factor product on haemophilia caregiver burden. Qual Life Res. 2018;27(5):1335-1345.
GOV.UK. Health and Social Care Act 2012: fact sheets - Publications - GOV.UK. [online] 2012; https://www.gov.uk/government/publications/health-and-social-care-act-2012-fact-sheets. Accessed October 20, 2018.
Chowdary P, Kearney S, Regnault A, Hoxer CS, Yees DL. Improvement in health-related quality of life in patients treated with ninacog betal pegol, a new extended half-life recombinant FIX product. Haemophilia. 2016;4:e267-e274.
Mancuso ME, Santagostino E. Outcome of clinical trials with new extended half-life FVIII/IX concentrates. J Clin Med. 2017;6(4):39.